Skip to main
AYTU
AYTU logo

Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioScience (AYTU) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aytu BioPharma Inc. presents an attractive current valuation with significant upside potential, as indicated by a positive net present value (NPV) analysis that supports an upward adjustment in the price target. The company has shown promising clinical trial results for its drug EXXUA, demonstrating substantial improvements in depression symptoms with minimal side effects, suggesting strong market viability. Additionally, the anticipated launch of EXXUA for the treatment of major depressive disorder in the fourth quarter of 2025 is viewed as a considerable catalyst for potential stock growth.

Bears say

Aytu BioPharma's stock is perceived to be undervalued, trading significantly below projected future sales, suggesting a disconnect between market performance and potential revenue growth. Despite the expansive market for antidepressants, with over 340 million prescriptions written in 2024, the company faces substantial competition and existing therapeutic challenges that could hinder its market penetration. Concerns regarding the company's financial stability and ability to capitalize on growth opportunities ultimately lead to a negative outlook for Aytu BioPharma's stock.

Aytu BioScience (AYTU) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aytu BioScience (AYTU) Forecast

Analysts have given Aytu BioScience (AYTU) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Aytu BioScience (AYTU) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aytu BioScience (AYTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.